Heo, J., Okusaka, T., Yoon, J., Sangro, B., Chan, S. L., Erinjeri, J. P., Matos, M., Decaens, T., Chen, E. X., Beg, M. S., Matilla, A. M., Phuong, L. T. T., Griffin, R., Udoye, S. I., Indiviglio, S., Kudo, M. (2025). Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + TACE and placebos (PBO) + TACE: EMERALD-1 subgroup analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.575